Upcoming
What is heading for approval, the dates to watch and what happened in the past year.
Phase 2: mid-stage trials
0Phase 3: final trials
11Filed with a regulator
2Approved in the past year
8RetatrutideEli LillyFiling with FDA planned for early 2027AmycretinNovo NordiskHead-to-head against semaglutide reads out in 2029EloralintideEli LillyPhase 3 readout dates not announcedMariTideAntibody conjugateAmgenPhase 3 readout dates not disclosedMazdutideInnovent Biologics (licensed from Eli Lilly)Approved in China in 2025. Its phase 3 trials are Chinese, with no US or EU filing.PemvidutideAltimmuneLiver trial reads out in 2029PetrelintideZealand Pharma and RocheThree phase 3 trials started in 2026SurvodutideBoehringer Ingelheim (from Zealand Pharma)Heart-outcomes result due by the end of 2026; liver trials runningCagrilintideNovo NordiskStandalone amylin analogue for obesity in the phase 3 RENEW program. Separate from the CagriSema combination.Source: Novo NordiskEnicepatide (CT-388)RocheGLP-1/GIP peptide for obesity in phase 3 ENITH-1/2. Diabetes and cardiovascular-outcome trials are planned for the first half of 2027.Source: Roche (2026-09-22)VK2735Viking TherapeuticsGLP-1/GIP peptide for obesity. Injectable VANQUISH and oral SUNRISE phase 3 trials are running. Not approved.Source: Viking Therapeutics (2026-10-14)
SemaglutideNovo NordiskNew forms: Wegovy pill (US Dec 2025, EU Jul 2026) and the 7.2 mg doseOrforglipronNot a peptideEli LillyApproved in the US (Apr 2026) and UK (Aug 2026)EnlicitideMerckFirst PCSK9 blocker in a daily pill, approved in the US (Jul 2026)IcotrokinraJohnson & Johnson (with Protagonist)First oral peptide for psoriasis, approved in the US (Mar 2026) and EU (Sep 2026)RusfertideTakeda (with Protagonist)Approved in the US for polycythemia vera (Aug 2026)SetmelanotideRhythm PharmaceuticalsNew use: obesity after hypothalamic injury (US Mar 2026; EU, UK, Japan and Canada since)EcnoglutideSciwind BiosciencesGLP-1 peptide for weight management, approved in China in March 2026. This approval applies to China.Source: Sciwind Biosciences (2026-03-06)Navepegritide (Yuviwel)Ascendis PharmaCNP prodrug with accelerated US approval in February 2026 for growth in children aged 2+ with achondroplasia and open growth plates. Clinical benefit still requires confirmation.Source: Ascendis Pharma (2026-02-27)
Additional entries checked: 22 Oct 2026
- Late 2026Phase 3 result for thymosin beta-4 eye drops in neurotrophic keratitis (SEER-2), expected November.TB-500
- 18 Nov 2026NICE guidance on orforglipron for the NHS in England.Orforglipron
- Dec 2026Expected European Commission decision on orforglipron, about two months after the EMA committee backed it.Orforglipron
- By end of 2026Novo Nordisk expects an FDA decision on CagriSema.CagriSema
- By end of 2026FDA decision on the 25 mg semaglutide pill for type 2 diabetes.Semaglutide
- By end of 2026Survodutide heart-outcomes result (SYNCHRONIZE-CVOT).Survodutide
- By February 2027FDA advisers review GHK-Cu, LL-37, dihexa, melanotan II and PEG-MGF for pharmacy compounding.GHK-Cu, LL-37, Dihexa, Melanotan II
- Early 2027Lilly plans to file retatrutide with FDA.Retatrutide
- Late 2027Phase 3 result for elamipretide in dry age-related macular degeneration (ReNEW).Elamipretide
- First half of 2028Phase 3 result for high-dose CagriSema.CagriSema
- First half of 2029Phase 3 result for amycretin against semaglutide (AMAZE 8).Amycretin
- 2029Phase 3 result for pemvidutide in fatty liver disease (PERFORMA).Pemvidutide
Dates are company or regulator guidance and often slip.
- 16 Oct 2026FilingEMA committee recommended approving orforglipron (Foundayo) in the EU.Orforglipron
- 7 Oct 2026Trial resultPetrelintide cut weight by up to 9.2% at 28 weeks against 2.0% on placebo in people with type 2 diabetes (ZUPREME-2). Zealand and Roche have started three phase 3 trials with about 7,000 people.Petrelintide
- 1 Oct 2026Trial resultSurvodutide cut weight by up to 13.1% in people with type 2 diabetes (SYNCHRONIZE-2).Survodutide
- 22 Sep 2026ApprovalHealth Canada approved setmelanotide (Imcivree) for obesity after hypothalamic injury. The UK and Japan did the same in August.Setmelanotide
- 21 Sep 2026Trial resultLow-dose CagriSema beat low-dose tirzepatide on weight in type 2 diabetes (REIMAGINE 5).CagriSema
- 18 Sep 2026ApprovalEU authorized icotrokinra (Icotyde) for plaque psoriasis.Icotrokinra
- Aug 2026ApprovalFDA approved rusfertide (Mimrylo) for polycythemia vera.Rusfertide
- Aug 2026ApprovalFDA added cardiovascular risk reduction to the Mounjaro (tirzepatide) label.Tirzepatide
- 24 Aug 2026RegulationFDA sent warning letters to five sellers of research-use-only peptides and rejected the research label as a defense.Retatrutide, Tesamorelin, Elamipretide, Bremelanotide, Survodutide, Mazdutide
- 10 Aug 2026ApprovalUK authorized orforglipron (Foundayo), the first regulator in Europe to do so.Orforglipron
- 24 Jul 2026RegulationFDA advisers backed pharmacy compounding of BPC-157, TB-500, KPV, MOTS-c, epitalon and semax, against FDA staff advice. They rejected DSIP. FDA had not acted on the votes by late September 2026.BPC-157, TB-500, KPV, MOTS-c, Epitalon, Semax, DSIP
- 23 Jul 2026Trial resultRetatrutide phase 3 results: 20.8% weight loss in people with type 2 diabetes and 22.6% in people with heart disease.Retatrutide
- Jul 2026ApprovalFDA approved enlicitide (Lipfendra), the first PCSK9 blocker taken as a daily pill.Enlicitide
- 14 Jul 2026ApprovalEuropean Commission approved the Wegovy pill (oral semaglutide 25 mg).Semaglutide
- 13 Jul 2026ApprovalHealth Canada approved afamelanotide (Scenesse) for adults with erythropoietic protoporphyria, a rare disease that makes sunlight painful.Afamelanotide
- Jun 2026ApprovalUK approved the Wegovy pill for weight management.Semaglutide
- 21 May 2026Trial resultRetatrutide averaged 28.3% weight loss at 80 weeks on the top dose (TRIUMPH-1).Retatrutide
- 1 May 2026ApprovalRhythm announced EU authorization of setmelanotide (Imcivree) for obesity after hypothalamic injury.Setmelanotide
- Apr 2026ApprovalHealth Canada approved the first generic semaglutide.Semaglutide
- 15 Apr 2026RegulationFDA said 12 peptides would leave its list of compounding safety risks because their nominations were withdrawn, and scheduled advisory committee meetings.BPC-157, TB-500, KPV, MOTS-c, Epitalon, Semax, DSIP, GHK-Cu, LL-37, Dihexa, Melanotan II
- 1 Apr 2026ApprovalFDA approved orforglipron (Foundayo), a daily GLP-1 pill that is not a peptide.Orforglipron
- 26 Mar 2026ApprovalEU granted semaglutide a conditional authorization for fatty liver disease with scarring (MASH), under the brand Kayshild.Semaglutide
- 19 Mar 2026ApprovalFDA approved the 7.2 mg dose of Wegovy.Semaglutide
- 19 Mar 2026ApprovalFDA approved setmelanotide (Imcivree) for obesity after hypothalamic injury.Setmelanotide
- 19 Mar 2026Trial resultRetatrutide lowered HbA1c by up to 2.0 points in type 2 diabetes (TRANSCEND-T2D-1).Retatrutide
- 17 Mar 2026ApprovalFDA approved icotrokinra (Icotyde), a once-daily peptide pill for plaque psoriasis.Icotrokinra
- 5 Mar 2026Trial resultPetrelintide cut weight by up to 10.7% at 42 weeks, with side effects similar to placebo (ZUPREME-1).Petrelintide
- 23 Feb 2026Trial resultCagriSema failed to show it was as good as tirzepatide in a head-to-head trial (REDEFINE 4).CagriSema
- Feb 2026ApprovalEuropean Commission approved the 7.2 mg dose of Wegovy.Semaglutide
- 22 Dec 2025ApprovalFDA approved the Wegovy pill, the first oral GLP-1 for weight management.Semaglutide
- 18 Dec 2025FilingNovo Nordisk filed CagriSema with FDA.CagriSema
- 11 Dec 2025Trial resultFirst retatrutide phase 3 result: 28.7% weight loss at 68 weeks in people with knee arthritis (TRIUMPH-4).Retatrutide
- 6 Nov 2025Trial resultEloralintide cut weight by up to 20.1% at 48 weeks in phase 2.Eloralintide